[1] Heusch P, Buchbender C, Köhler J, et al.  Thoracic Staging in Lung Cancer: Prospective Comparison of 18F-FDG PET/MR Imaging and 18F-FDG PET/CT[J]. J Nucl Med, 2014, 55(3): 373-378.   doi: 10.2967/jnumed.113.129825
[2] Lee RJ, Lee SA, Lin T, et al.  Determining the epidemiologic, outcome, and prognostic factors of oral malignant melanoma by using the Surveillance, Epidemiology, and End Results database[J]. J Am Dent Assoc, 2017, 148(5): 288-297.   doi: 10.1016/j.adaj.2017.01.019
[3] Stanienda-Sokół K, Salwowska N, Sławińska M, et al.  Primary Locations of Malignant Melanoma Lesions Depending on Patients’ Gender and Age[J]. Asian Pac J Cancer Prev, 2017, 18(11): 3081-3086.   doi: 10.22034/APJCP.2017.18.11.3081
[4] Gershenwald JE, Scolyer RA, Hess KR, et al.  Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017, 67(6): 472-492.   doi: 10.3322/caac.21409
[5] Garbe C, Peris K, Hauschild A, et al.  Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—Update 2012[J]. Eur J Cancer, 2012, 48(15): 2375-2390.   doi: 10.1016/j.ejca.2012.06.013
[6] Dummer R, Hauschild A, Guggenheim M, et al.  Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 21 Suppl 5: Sv194-v197.   doi: 10.1093/annonc/mdq188
[7] Dummer R, Hauschild A, Guggenheim M, et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23 Suppl 7: Svii86-vii91.   doi: 10.1093/annonc/mds229
[8] 胡莹莹, 林晓平, 梁培炎, 等.  18F-FDG PET/CT在恶性黑色素瘤诊断及分期中的应用价值[J]. 中国医学影像技术, 2009, 25(4): 685-688.   doi: 10.3321/j.issn:1003-3289.2009.04.048
Hu YY, Lin XP, Liang PY, et al.  Application of 18F-FDG PET/CT in diagnosis and staging of malignant melanoma[J]. Chin J Med Imaging Technol, 2009, 25(4): 685-688.   doi: 10.3321/j.issn:1003-3289.2009.04.048
[9] 宋建华, 赵晋华, 邢岩, 等.  18F-FDG PET/CT对原发不明颈部淋巴结转移癌患者原发灶检出的价值[J]. 中华核医学与分子影像杂志, 2013, 33(6): 417-420.   doi: 10.3760/cma.j.issn.2095-2848.2013.06.004
Song JH, Zhao JH, Xing Y, et al.  18F-FDG PET/CT for the detection of primary malignancy in patients with cervical lymph node metastatses from unknown origin[J]. Chin J Nucl Med Mol imaging, 2013, 33(6): 417-420.   doi: 10.3760/cma.j.issn.2095-2848.2013.06.004
[10] Haerle SK, Soyka MB, Fischer DR, et al.  The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma[J]. Eur Arch Otorhinolaryngol, 2012, 269(1): 127-133.   doi: 10.1007/s00405-011-1664-1
[11] Morton DL, Cochran AJ, Thompson JF, et al.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial[J]. Ann Surg, 2005, 242(3): 302-311.
[12] Crippa F, Leutner M, Belli F, et al.  Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma[J]. J Nucl Med, 2000, 41(9): 1491-1494.
[13] Krug B, Crott R, Lonneux M, et al.  Role of PET in the initial staging of cutaneous malignant melanoma: systematic review[J]. Radiology, 2008, 249(3): 836-844.   doi: 10.1148/radiol.2493080240
[14] Schüle SC, Eigentler TK, Garbe C, et al.  Influence of 18F-FDG PET/CT on therapy management in patients with stage Ⅲ/Ⅳ malignant melanoma[J]. Eur J Nucl Med Mol Imaging, 2016, 43(3): 482-488.   doi: 10.1007/s00259-015-3187-2
[15] Xing Y, Bronstein Y, Ross MI, et al.  Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis[J]. J Natl Cancer Inst, 2011, 103(2): 129-142.   doi: 10.1093/jnci/djq455
[16] Jouvet JC, Thomas L, Thomson V, et al.  Whole-body MRl with diffusion-weighted sequences compared with 18FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study[J]. J Eur Acad Dermatol Venereal, 2014, 28(2): 176-185.   doi: 10.1111/jdv.12078
[17] Reinhardt MJ, Joe AY, Jaeger U, et al.  Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients[J]. J Clin Oncol, 2006, 24(7): 1178-1187.   doi: 10.1200/JCO.2005.03.5634
[18] Aukema TS, Valdés ORA, Wouters MW, et al.  Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases[J]. Ann Surg Oncol, 2010, 17(10): 2773-2778.   doi: 10.1245/s10434-010-1088-y
[19] Bronstein Y, Ng CS, Rohren E, et al.  PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging[J]. AJR Am J Roentgenol, 2012, 198(4): 902-908.   doi: 10.2214/AJR.11.7280
[20] Danielsen M, Højgaard L, Kjær A, et al.  Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review[J]. Am J Nucl Med Mol Imaging, 2013, 4(1): 17-28.
[21] Wieder HA, Tekin G, Rosenbaum-Krumme S, et al.  18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma[J]. Nuklearmedizin, 2013, 52(5): 198-203.   doi: 10.3413/Nukmed-0584-13-05
[22] Rueth NM, Xing Y, Chiang YJ, et al.  Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies[J]. Ann Surg, 2014, 259(6): 1215-1222.   doi: 10.1097/SLA.0000000000000233
[23] Galgano SJ, Marchall RV, Middlebrooks EH, et al.  PET/MR Imaging in Head and Neck Cancer: Current Applications and Future Directions[J]. Magn Reson Imaging Clin N Am, 2018, 26(1): 167-178.   doi: 10.1016/j.mric.2017.08.010
[24] Buchbender C, Heusner TA, Lauenstein TC, et al.  Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma[J]. J Nucl Med, 2012, 53(8): 1244-1252.   doi: 10.2967/jnumed.112.109306
[25] Petralia G, Padhani A, Summers P, et al.  Whole-body diffusion-weighted imaging: Is it all we need for detecting metastases in melanoma patients?[J]. Eur Radiol, 2013, 23(12): 3466-3476.   doi: 10.1007/s00330-013-2968-x
[26] Wagner M, Mariani P, Bidard FC, et al.  Diffusion-weighted MRI for uveal melanoma liver metastasis detection[J]. Eur Radiol, 2015, 25(8): 2263-2273.   doi: 10.1007/s00330-015-3662-y
[27] Mosavi F, Ullenhag G, Ahlström H.  Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma[J]. Ups J Med Sci, 2013, 118(2): 91-97.   doi: 10.3109/03009734.2013.778375
[28] Murphy G, Hussey D, Metser U.  Non-cutaneous melanoma: Is there a role for 18F-FDG PET-CT?[J]. Br J Radiol, 2014, 87(1040): 20140324-.   doi: 10.1259/bjr.20140324
[29] Laforga Canales JB, Gasent Blesa JM.  Amelanotic Anorectal Malignant Melanoma: Case Report with Immunohistochemical Study and Literature Review[J]. Case Rep Oncol, 2009, 2(1): 30-37.   doi: 10.1159/000204788
[30] Tartaglione T, Pagliara MM, Sciandra M, et al.  Uveal melanoma: evaluation of extrascleral extension using thin-section MR of the eye with surface coils[J]. Radiol Med, 2014, 119(10): 775-783.   doi: 10.1007/s11547-014-0388-x
[31] Erb-Eigner K, Warmuth C, Taupitz M, et al.  Impact of magnetic field strength and receiver coil in ocular MRI: a phantom and patient study[J]. Rofo, 2013, 185(9): 830-837.   doi: 10.1055/s-0033-1335796
[32] Calcagni ML, Mattoli MV, Blasi MA, et al.  A prospective analysis of 18F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features[J]. Eur J Nucl Med Mol Imaging, 2013, 40(11): 1682-1691.   doi: 10.1007/s00259-013-2488-6
[33] Klingenstein A, Haug AR, Nentwich MM, et al.  Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma[J]. Melanoma Res, 2010, 20(6): 511-516.   doi: 10.1097/CMR.0b013e3283403d6c
[34] Orcurto V, Denys A, Voelter V, et al.  18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study[J]. Melanoma Res, 2012, 22(1): 63-69.   doi: 10.1097/CMR.0b013e32834d3dcb
[35] Collaborative Ocular Melanoma Study Group.  Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15[J]. Arch Ophthalmol, 2001, 119(5): 670-676.   doi: 10.1001/archopht.119.5.670
[36] Strobel K, Bode B, Dummer R, et al.  Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma[J]. Eur J Nucl Med Mol Imaging, 2009, 36(11): 1774-1782.   doi: 10.1007/s00259-009-1175-0
[37] Merelli B, Massi D, Cattaneo L, et al.  Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities[J]. Crit Rev Oncol Hematol, 2014, 89(1): 140-165.   doi: 10.1016/j.critrevonc.2013.08.002
[38] Hamid O, Robert C, Daud A, et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma[J]. N Engl J Med, 2013, 369(2): 134-144.   doi: 10.1056/NEJMoa1305133
[39] Gibney GT, Zager JS.  Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies[J]. Expert Opin Drug Metab Toxicol, 2013, 9(7): 893-899.   doi: 10.1517/17425255.2013.794220
[40] Chapman PB, Robert C, Larkin J, et al.  Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study[J]. Ann Oncol, 2017, 28(10): 2581-2587.   doi: 10.1093/annonc/mdx339
[41] Wolchok JD, Hoos A, O'Day S, et al.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria[J]. Clin Cancer Res, 2009, 15(23): 7412-7420.   doi: 10.1158/1078-0432.CCR-09-1624
[42] Flaherty KT, Puzanov I, Kim KB, et al.  Inhibition of mutated, activated BRAF in metastatic melanoma[J]. N Engl J Med, 2010, 363(9): 809-819.   doi: 10.1056/NEJMoa1002011
[43] Uhrig M, Hassel JC, Schlemmer HP, et al.  Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST[J]. Acad Radiol, 2013, 20(4): 423-429.   doi: 10.1016/j.acra.2012.09.029
[44] Guerreschi P, Scalbert C, Qassemyar A, et al.  Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma[J]. Melanoma Res, 2013, 23(5): 373-380.   doi: 10.1097/CMR.0b013e328363ed92
[45] Geven EJ, Evers S, Nayak TK, et al.  Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of 18F-FDG-PET and 18F-FLT-PET[J]. Contrast Media Mol Imaging, 2015, 10(3): 203-210.   doi: 10.1002/cmmi.1619
[46] Larkin J, Del Vecchio M, Ascierto PA, et al.  Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study[J]. Lancet Oncol, 2014, 15(4): 436-444.   doi: 10.1016/S1470-2045(14)70051-8
[47] Lacouture ME, Wolchok JD, Yosipovitch G, et al.  Ipilimumab in patients with cancer and the management of dermatologic adverse events[J]. J Am Acad Dermatol, 2014, 71(1): 161-169.   doi: 10.1016/j.jaad.2014.02.035
[48] Bronstein Y, Ng CS, Hwu P, et al.  Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy[J]. AJR Am J Roentgenol, 2011, 197(6): W992-W1000.   doi: 10.2214/AJR.10.6198
[49] Murphy KP, Kennedy MP, Barry JE, et al.  New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment[J]. Oncol Res Treat, 2014, 37(6): 351-353.   doi: 10.1159/000362614
[50] Beloueche-Babari M, Jamin Y, Arunan V, et al.  Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI[J]. Br J Cancer, 2013, 109(6): 1562-1569.   doi: 10.1038/bjc.2013.456
[51] Cheng Z, Zhang L, Graves E, et al.  Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog[J]. J Nucl Med, 2007, 48(6): 987-994.   doi: 10.2967/jnumed.107.039602
[52] 冯洪燕, 兰晓莉, 夏晓天, 等.  恶性黑色素瘤新型正电子显像剂18F-5-FPN的制备及临床前研究[J]. 中华核医学与分子影像杂志, 2016, 36(2): 116-121.   doi: 10.3760/cma.j.issn.2095-2848.2016.02.005
Feng HY, Lan XL, Xia XT, et al.  Preparation and preclinical study of 18F-5-FPN imaging for malignant melanoma[J]. Chin J Nucl Med Mol Imaging, 2016, 36(2): 116-121.   doi: 10.3760/cma.j.issn.2095-2848.2016.02.005
[53] Kim KB, Prieto V, Joseph RW, et al.  A randomized phase Ⅱ study of cilengitide (EMD 121974) in patients with metastatic melanoma[J]. Melanoma Res, 2012, 22(4): 294-301.   doi: 10.1097/CMR.0b013e32835312e4
[54] Mena E, Owenius R, Turkbey B, et al.  [18F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ3 and αvβ5 integrins[J]. Eur J Nucl Med Mol Imaging, 2014, 41(10): 1879-1888.   doi: 10.1007/s00259-014-2791-x
[55] Xie L, Yui J, Fujinaga M, et al.  Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe 18F-FITM[J]. Int J Cancer, 2014, 135(8): 1852-1859.   doi: 10.1002/ijc.28842
[56] Qin C, Liu H, Chen K, et al.  Theranostics of malignant melanoma with 64CuCl2[J]. J Nucl Med, 2014, 55(5): 812-817.   doi: 10.2967/jnumed.113.133850